Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2

Neurocrine Biosciences announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep, or EE-CSWS. NBI-827104 was generally well tolerated.